According to the company, the model is part of the company’s effort to develop a portfolio of clinically relevant models and biomaterials for therapeutic discovery and development.
“This is the first launch in a series of novel in vitro systems that employ state-of-the-art gene editing techniques to address specific disease and resistance mechanisms in cancer,” the company said in a press release.
The new model – ATCC CCL-185EMT – is a lung cancer EMT (epithelial-to-mesenchymal transition) model built on the ATCC A549 lung cancer cell line.
According to the company, the model is a fluorescent reporter cell line, which enables researchers to track the cellular mechanisms relevant to cancer metastasis. It also allows researchers to evaluate the effects of potential anti-cancer drugs using high-throughput methods, ATCC said.
Expanding CRO services
ATCC signed a strategic agreement with the contract research organization (CRO) BioAgilytix in October 2016. The company told us at the time that it has recently launched an initiative to provide biological-based CRO services.
“One of our strategic goals is to develop additional scientifically-relevant products and services, and key to that goal is the expansion of our custom biological-based contract research organization services and standards,” he said.